United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant… byPallavi MadhirajuJune 25, 2023